NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $8.43 -0.12 (-1.37%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Trevi Therapeutics Stock (NASDAQ:TRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$8.36▼$8.6050-Day Range$6.71▼$9.7552-Week Range$2.36▼$9.92Volume391,894 shsAverage Volume1.99 million shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$21.75Consensus RatingBuy Company Overview Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions. Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy. In addition to its TTX program, Trevi maintains a pipeline of preclinical and discovery-stage assets aimed at broadening treatment options for patients with refractory pain syndromes. Headquartered in San Diego, California, Trevi Therapeutics conducts research and development activities at its U.S. facilities and collaborates with academic institutions and contract research organizations to advance its clinical candidates. The company’s leadership team combines expertise in pharmaceutical development, regulatory affairs and commercialization strategy to guide its growth as a specialty biopharmaceutical innovator.AI Generated. May Contain Errors. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreTRVI MarketRank™: Trevi Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 697th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingBuy Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Upside PotentialTrevi Therapeutics has a consensus price target of $21.75, representing about 158.3% upside from its current price of $8.42.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -20.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -20.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 6.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.74% of the float of Trevi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 15.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.74% of the float of Trevi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 15.53%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Trevi Therapeutics this week, compared to 5 articles on an average week.Search Interest17 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Stock News HeadlinesHow Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025September 20 at 1:59 PM | finance.yahoo.comTrevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025September 18, 2025 | prnewswire.comThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.September 23 at 2:00 AM | Brownstone Research (Ad)Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.75September 12, 2025 | americanbankingnews.comHaduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan StanleySeptember 11, 2025 | msn.comTrevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comTrevi spikes as B. Riley reportedly cites deal prospectsAugust 28, 2025 | msn.comTrevi Therapeutics to Participate in Upcoming September ConferencesAugust 28, 2025 | prnewswire.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $4.12 on January 1st, 2025. Since then, TRVI shares have increased by 104.4% and is now trading at $8.4210. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' top institutional shareholders include Rubric Capital Management LP (7.01%), Vivo Capital LLC (3.69%), Alliancebernstein L.P. (3.52%) and Octagon Capital Advisors LP (3.02%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC). Company Calendar Last Earnings8/07/2025Today9/23/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Trevi Therapeutics$21.75 High Price Target$27.00 Low Price Target$18.00 Potential Upside/Downside+157.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.44% Return on Assets-38.21% Debt Debt-to-Equity RatioN/A Current Ratio22.42 Quick Ratio22.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book6.49Miscellaneous Outstanding Shares121,780,000Free Float99,492,000Market Cap$1.03 billion OptionableOptionable Beta0.71 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:TRVI) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.